Journal
CLINICAL CANCER RESEARCH
Volume 22, Issue 21, Pages 5164-5166Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-16-1666
Keywords
-
Categories
Funding
- NCI NIH HHS [T32 CA009111, R01 CA177476, P01 CA154291, P50 CA190991] Funding Source: Medline
- NINDS NIH HHS [U01 NS090284, R01 NS085412, R25 NS065731, R01 NS086943] Funding Source: Medline
Ask authors/readers for more resources
Oncolytic viruses, proteasome inhibitors, and natural killer (NK)-cell immunotherapy have all been studied extensively as monotherapies but have never been evaluated in combination. Synergetic treatment of oncolytic virus-infected glioblastomas with a proteasome inhibitor induces necroptotic cell death to enhance NK-cell immunotherapy, prolonging survival against human glioblastoma. (C) 2016 AACR.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
